ALK Abello Reports 18% Revenue Growth in Q2 2026, Lifts Full-Year Outlook
Event summary
- ALK Abello reported 18% organic revenue growth in Q2 2026, with operating profit (EBIT) up 19% to DKK 445 million.
- Tablet sales grew 22% to DKK 1,013 million, driven by pediatric roll-out and strong regional performance.
- Anaphylaxis product sales surged 26% to DKK 267 million, boosted by Jext®.
- Free cash flow for H1 2026 increased to DKK 889 million, with a net debt to EBITDA ratio of -0.6.
- Full-year revenue outlook updated to 14-16% growth (previously 13-16%) due to strong tablet sales momentum.
The big picture
ALK Abello's strong Q2 2026 performance reflects sustained demand for its allergy treatments, particularly in pediatric markets. The company's strategic focus on expanding product lines and securing regulatory approvals positions it well in the competitive allergy treatment space. With updated full-year guidance, ALK is signaling confidence in its growth trajectory despite rising investment costs.
What we're watching
- Regulatory Progress
- Whether ALK can secure phase 3 trial initiation for the peanut tablet by late 2026.
- Market Expansion
- The pace at which neffy® nasal adrenaline spray gains approval in additional markets.
- Operational Efficiency
- How ALK balances increased R&D and marketing investments with maintaining EBIT margins.
Related topics